Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today provided an update on its ongoing OVATION study, a Phase Ib dose...
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, 2016 and...
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended...
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced data from the first cohort of patients in its Phase Ib dose ...
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the first patient in China has been enrolled in its...
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that preclinical data for GEN-1 in combination with...
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that data highlighting the potential of GEN-1 in ovarian...
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2015 and...
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss year-end 2015 financial results and...
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that its preclinical data for GEN-1 in combination with...
Celsion Corporation (NASDAQ: CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments,...
Celsion Corporation (Celsion) (NASDAQ: CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer...
Celsion Corporation (NASDAQ: CLSN), today announced new translational data from its Phase 1b study of GEN-1 in patients with platinum-resistant...
Celsion Corporation (NASDAQ: CLSN) today announced that it has received Clinical Trial Application (CTA) approval from the China Food and Drug...
Celsion Corporation (NASDAQ: CLSN) today announced the presentation of results from its ongoing Phase I/II US DIGNITY Study of ThermoDox® in...
Celsion Corporation (NASDAQ: CLSN), a fully integrated oncology company focused on the development of a portfolio of innovative cancer treatments,...
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the quarter ended September 30, 2015...
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the presentation of data from the Company's HEAT Study,...
Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss its third quarter 2015 financial results...
Celsion Corporation (NASDAQ: CLSN) today announced that it will host a Research and Development (R&D) Day for investors and analysts on Tuesday,...
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today reported data from a large preclinical study of the Company's GEN-1...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.